Clinical considerations for the diagnosis of idiopathic hypersomnia

Y Dauvilliers, RK Bogan, I Arnulf, TE Scammell… - Sleep Medicine …, 2022 - Elsevier
Idiopathic hypersomnia is a sleep disorder of neurologic origin characterized by excessive
daytime sleepiness, with sleep inertia, long, unrefreshing naps, and prolonged nighttime …

Sleepiness in adults: An umbrella review of a complex construct

VP Martin, R Lopez, Y Dauvilliers, JL Rouas… - Sleep medicine …, 2023 - Elsevier
Sleepiness involves many dimensions that require investigation. Since sleepiness is often
defined operationally, we exhaustively inventoried all the assessment tools designed to …

Update on the treatment of idiopathic hypersomnia: progress, challenges, and expert opinion

I Arnulf, R Thomas, A Roy, Y Dauvilliers - Sleep Medicine Reviews, 2023 - Elsevier
Idiopathic hypersomnia is a central hypersomnolence disorder of unknown origin
characterized by excessive daytime sleepiness despite normal or long sleep time, and …

Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study

Y Dauvilliers, I Arnulf, N Foldvary-Schaefer… - The Lancet …, 2022 - thelancet.com
Background Idiopathic hypersomnia is a central hypersomnolence disorder mainly
characterised by excessive daytime sleepiness, with prolonged night-time sleep and …

Une approche multi-dimensionnelle de l'hypersomnolence

R Lopez, JA Micoulaud-Franchi, L Barateau… - Médecine du …, 2022 - Elsevier
Résumé L'hypersomnolence est un concept sémiologique dont les délimitations restent
incertaines. Elle est généralement définie par l'association à des degrés divers d'une …

Long-term efficacy and safety of low-sodium oxybate in an open-label extension period of a placebo-controlled, double-blind, randomized withdrawal study in adults …

AM Morse, Y Dauvilliers, I Arnulf, MJ Thorpy… - Journal of Clinical …, 2023 - jcsm.aasm.org
Study Objectives: To evaluate 6-month efficacy and safety of low-sodium oxybate in people
with idiopathic hypersomnia during an open-label extension period (OLE) of a phase 3 …

Symptom severity and treatment satisfaction in patients with idiopathic hypersomnia: the real world idiopathic hypersomnia outcomes study (ARISE)

LD Schneider, J Stevens, AM Husain, D Ito… - Nature and Science …, 2023 - Taylor & Francis
Objective Idiopathic hypersomnia is a debilitating sleep disorder characterized by excessive
daytime sleepiness, sleep inertia, and prolonged sleep duration. The patient burden of …

Efficacy and safety of lower-sodium oxybate in an open-label titration period of a phase 3 clinical study in adults with idiopathic hypersomnia

MJ Thorpy, I Arnulf, N Foldvary-Schaefer… - Nature and Science …, 2022 - Taylor & Francis
Purpose To report the efficacy and safety of lower-sodium oxybate (LXB; Xywav®) during the
open-label titration and optimization period (OLT) and stable-dose period (SDP) in a clinical …

Narcolepsy Severity Scale-2 and Idiopathic Hypersomnia Severity Scale to better quantify symptoms severity and consequences in Narcolepsy type 2

L Barateau, S Chenini, C Denis, Q Lorber, S Béziat… - Sleep, 2024 - academic.oup.com
Abstract Study Objectives Narcolepsy type 2 (NT2) is an understudied central disorder of
hypersomnolence sharing some similarities with narcolepsy type 1 and idiopathic …

Validation and performance of the sleep inertia questionnaire in central disorders of hypersomnolence

ER Sung, CB Maness, JD Cook, AM Vascan, D Moron… - Sleep Medicine, 2024 - Elsevier
Background Optimal measurement tools for problematic sleep inertia, common in some
central disorders of hypersomnolence (CDH), have not yet been determined. We evaluated …